SGX Collaborates with Novartis to Develop and Commercialize BCR-ABL Inhibitors
News Mar 29, 2006
SGX Pharmaceuticals, Inc. has announced that it has entered into a license and collaboration agreement with Novartis focused on the development and commercialization of BCR-ABL inhibitors for the treatment of drug resistant Chronic Myelogenous Leukemia (CML).
Under the terms of the agreement, SGX will receive from Novartis $25 million in upfront payments and the purchase of SGX common stock.
Along with milestones, but excluding royalties, total payments to SGX could exceed $515 million, including a minimum of two years of research funding.
The success of Gleevec™ (imatinib), the first targeted therapy in Philadelphia Positive (Ph+CML) proven to inhibit BCR-ABL, has fundamentally changed the treatment of Ph+CML.
However, a subset of patients develops resistance to Gleevec or cannot tolerate therapy. For these patients there are currently no other approved treatment options.
Drug candidates from SGX's lead series, developed from its FAST™ proprietary drug discovery platform, have exhibited activity against wild-type and drug resistant BCR-ABL mutants, including the T315I mutant.
"Novartis is the leader in developing novel targeted therapies to treat CML," said Mike Grey, president and chief executive officer of SGX Pharmaceuticals.
"With their extensive experience developing and commercializing Gleevec as well as development of the novel investigational compound, nilotinib/AMN107, we believe they are the ideal partner with whom to develop our series of next-generation BCR-ABL inhibitors."
"This is a tremendous validation of our FAST technology for generation of novel lead molecules for key therapeutic targets."
SGX will be responsible for completing preclinical development of the lead candidate and submitting an Investigational Drug application with the Food and Drug Administration.
SGX will also be responsible for the completion of an initial phase I clinical study, after which time Novartis will be responsible for conducting further clinical development and commercialization of the compound.
In addition to the upfront and milestone payments, SGX will receive royalty payments upon commercialization of products developed under the collaboration.
SGX retains an option to co-commercialize, in the U.S., oncology products developed under the agreement.
If exercised, the option would enable SGX to reinforce the commercial presence in the North American hematology markets which the company plans to establish with the potential launch of Troxatyl™ in the second half of 2007, assuming the completion of the ongoing Phase II/III clinical trial for the treatment of third-line acute myelogenous leukemia and regulatory approval of Troxatyl for this initial indication in 2007.
"We believe that a BCR-ABL inhibitor developed through this collaboration could have the potential to be used both as a monotherapy in second-line treatment of refractory or relapsed CML, and in combination with Gleevec or another agent in first-line treatment of CML," added Dr. Stephen Burley, chief scientific officer of SGX Pharmaceuticals.